Classify Asthma Severity
Assessing severity and initiating treatment for patients who are not currently taking long-term control medications
Criador
The National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)Introduction
The National Asthma Education and Prevention Program (NAEPP) was initiated in 1989 to address the growing national health problem of asthma, which remains a significant problem today. The National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC) provides a venue for convening diverse stakeholders with an interest in improving asthma management in the context of current standards of care. The NAEPPCC first developed and widely disseminated the guidelines for diagnosing and managing asthma in 1991, followed by revisions in 1997, 2002, 2007, and 2020. The most recent update to these guidelines, the 2020 Focused Updates to the Asthma Management Guidelines, provides guidance on six selected topic areas.
The NAEPP’s former National Asthma Control Initiative (NACI) engaged diverse stakeholders to bring asthma care in line with evidence-based recommendations. NAEPP and NACI resources for patients with asthma and their families and for health professionals are still available.
The NAEPPCC consists of representatives from the major scientific, professional, governmental, and voluntary organizations interested in asthma. The Committee’s primary mission is to advise the NHLBI on matters concerning asthma and to facilitate the exchange of information on asthma activities among the member agencies and voluntary health organizations.
The NHLBI administers and coordinates the NAEPPCC. These NAEPPPCC’s meetings are open to the public and include presentations and discussions on a variety of topics concerning asthma, including activities and projects of the Committee. View details about NAEPPCC meetings and materials.
The Classify Asthma Severity tool can be used for:
patients not currently treated for asthma or
the patient's treatment plan is unknown or
the patient is not taking asthma controller medications as prescribed for at least three months.
Recommendations
The Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma details how to assess asthma severity and determine the appropriate treatment step during the initial visit of a newly diagnosed asthma patient.
The Classify Asthma Severity tool can be used for:
patients not currently treated for asthma or
the patient's treatment plan is unknown or
the patient is not taking asthma controller medications as prescribed for at least three months.
Assessing asthma severity and initiating therapy is based on the most severe impairment or risk category.
Classification of Asthma Severity (≥12 years of age and older)
See Figure 4-6
Classification of Asthma Severity (5-11 years of age)
See Figure 3-4b
Classification of Asthma Severity (0-4 years of age)
See Figure 4-2a
The new EPR-4 Asthma Treatment Guidelines stipulate that patients age 4 years old will follow treatment recommendations for ages 5-11 years old for steps 3 & 4. This decision tool will incorporate the new EPR-4 recommendations by including recommendations for ages 4-11 that involve step 3 and 4.
Todas as perguntas e resultados possíveis
AgeTítulo não visível
Choose age group
Select one option:
- 0-3 years old
- 4 years old
- 5-11 years old
- 12+ years old
Assess Pre-exacerbation Severity (Ages12+)
These are pre-exacerbation questions that are meant to determine how the patient was doing before the exacerbation event.
Daytime symptoms
Select one option:
- throughout the day
- daily
- > 2 days/week, not daily
- ≤ 2 days/week
Nighttime symptoms
Select one option:
- often 7x week
- > 1x/week but not nightly
- 3-4x/month
- ≤ 2x/month
Exacerbations requiring oral steroids
Select one option:
- ≥ 2 per year
- 0-1/year
Short-acting beta agonist (SABA) for symptom control (not exercise induced)
Select one option:
- several times a day
- daily
- > 2 days/week but not daily, and not more than 1x on any day
- ≤ 2 days a week
Interference with normal activity
Select one option:
- extremely limited
- some limitation
- minor limitation
- none
Select Lung Function (optional)
Intermittent | Mild Persistent | Moderate Persistent | Severe Persistent |
|
|
|
|
*Normal FEV₁/FVC
8-19 yr 85%
20-39 yr 80%
40-59 yr 75%
60-80 yr 70%
Select one option:
- Severe Persistent
- Moderate Persistent
- Mild Persistent
- Intermittent
- Unknown
Assess Pre-exacerbation Severity (Ages 5-11)
These are pre-exacerbation questions that are meant to determine how the patient was doing before the exacerbation event.
Daytime symptoms
Select one option:
- throughout the day
- daily
- > 2 days/week, not daily
- ≤ 2 days/week
Nighttime symptoms
Select one option:
- Often 7x/week
- > 1x/week but not nightly
- 3-4x/month
- ≤ 2x/month
Exacerbations requiring oral steroids
Select one option:
- ≥ 2 per year
- 0-1/year
Short-acting beta agonist (SABA) for symptom control (not exercise induced)
Select one option:
- several times a day
- daily
- > 2 days/week but not daily, and not more than 1x on any day
- ≤ 2 days a week
Interference with normal activity
Select one option:
- extremely limited
- some limitation
- minor limitation
- none
Select Lung function (optional)
| Intermittent | Mild Persistent | Moderate Persistent | Severe Persistent |
|
|
|
|
Select one option:
- Severe Persistent
- Moderate Persistent
- Mild Persistent
- Intermittent
- Unknown
Assess Pre-exacerbation Severity (Ages 0-4)
These are pre-exacerbation questions that are meant to determine how the patient was doing before the exacerbation event.
Daytime symptoms
Select one option:
- throughout the day
- daily
- > 2 days/week, not daily
- ≤ 2 days/week
Nighttime symptoms
Select one option:
- > 1x/week
- 3-4x/month
- 1-2x/month
- 0
Short-acting beta-agonist use for symptom control (not exercise induced)
Select one option:
- several times per day
- daily
- > 2 days/week but not daily
- ≤ 2 days/week
Interference with normal activity
Select one option:
- Extremely limited
- some limitation
- minor limitation
- none
Exacerbations requiring oral steroids
Select one option:
- ≥ 2 exacerbations in 6 months requiring oral systemic corticosteroids, or ≥ 4 wheezing episodes/1 year lasting > 1 day AND risk factors for persistent asthma
- 0-1/year
Resultados possíveis
Intermittent (Ages 5-11): Initiate treatment at Step 1. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.
Severe Persistent (Ages 5-11): Initiate step 3 or step 4. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.
EPR-3 Assess Severity Guideline Summary
Note: The EPR-4 guidelines now recommend SMART Therapy (Step 3) as the preferred treatment over the EPR-3 medium-dose ICS option (now considered an alternative therapy in step 3 EPR-4 guidelines).
EPR-4 Step Therapy Guideline Summary
Severe Persistent (Ages 0-4): Initiate treatment at Step 3. In 2-6 weeks, evaluate level of asthma control and adjust therapy accordingly. If no clear benefit in 4-6 weeks, consider adjusting therapy or alternative diagnosis.
EPR-3 Assess Severity Guideline Summary
EPR-4 Step Therapy Guideline Summary (Ages 0-4)
EPR-4 Step Therapy Guideline Summary (Ages 5-11)
Note: Age 4 will follow therapy guidelines for ages 5-11 for step 3 & 4.
Moderate Persistent (Ages 12+): Initiate treatment at Step 3. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.
Mild Persistent (Ages 0-4): Initiate treatment at Step 2. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly. If no clear benefit in 4-6 weeks, consider adjusting therapy or alternative diagnosis.
Intermittent (Ages 0-4): Initiate treatment at Step 1. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly. If no clear benefit in 4-6 weeks, consider adjusting therapy or alternative diagnosis.
Severe Persistent (Ages 12+): Initiate treatment at step 4 or 5. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.
Mild Persistent (Ages 5-11): Initiate treatment at Step 2. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.
Moderate Persistent (Ages 0-4): Initiate treatment at Step 3. In 2-6 weeks, evaluate level of asthma control and adjust therapy accordingly. If no clear benefit in 4-6 weeks, consider adjusting therapy or alternative diagnosis.
EPR-3 Assess Severity Guideline Summary
EPR-4 Step Therapy Guideline Summary (Ages 0-4)
EPR-4 Step Therapy Guideline Summary (Ages 5-11)
Note: Age 4 will follow therapy guidelines for ages 5-11 for step 3 & 4.
Mild Persistent (Ages 12+): Initiate treatment at Step 2. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.
Intermittent (Ages 12+): Initiate treatment at Step 1. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.
Moderate Persistent (Ages 5-11): Initiate treatment at Step 3. In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.
EPR-3 Assess Severity Guideline Summary
Note: The EPR-4 guidelines now recommend SMART Therapy (Step 3) as the preferred treatment over the EPR-3 medium-dose ICS option (now considered an alternative therapy in step 3 EPR-4 guidelines).
EPR-4 Step Therapy Guideline Summary
Literatura
Guidelines for the Diagnosis and Management of Asthma- Summary Report 2007
https://pubmed.ncbi.nlm.nih.gov/17983880/2020 Focused Updates to the Asthma Management Guidelines
https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates
Avaliações relacionadas
Assess Asthma Control & Adjust Therapy
Managing asthma long term
The National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)Asthma Inhaled Corticosteroid (ICS) Dose Strength Algorithm
Determine the strength (low, med, high) of an inhaled corticosteroid to correlate with an asthma therapy step.
The National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)Identify Current Asthma Treatment Step
Determine your patient's current asthma treatment step based on current medications.
The National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)COPD Assessment Test (CAT)
Quantifies COPD symptom burden on patients' functional status
Dr. Paul W. Jones, MD, PhDGlobal Initiative for Obstructive Lung Disease (GOLD) Criteria for COPD
Treatment recommendations based on COPD stage.
Global Initiative For Chronic Obstructive Lung Disease (GOLD)The RAND (v.1) 36-Item Short Form Survey Instrument (SF-36)
A 36-item, patient-reported survey (RAND v.1) measuring health status and quality of life across eight health domains.
Dr. John E. Ware Jr., PhDThe RAND 20-Item Short Form Health Survey (SF-20)
A 20-item, patient-reported survey (RAND v.1) measuring health status and quality of life across six health domains.
Dr. Anita L. Stewart, PhDmMRC (Modified Medical Research Council) Dyspnea Scale
Stratifies severity of dyspnea in respiratory diseases, such as COPD.
Dr. Donald A. Mahler, MDSTOP-BANG Score for Obstructive Sleep Apnea
Screens for obstructive sleep apnea
Dr. Frances Chung, MD, MBBS, LMCC, FRCPCTambém de EVAL Foundation
Alcohol Use Disorders Identification Test - C (AUDIT-C)
A 3-item tool to screen for unhealthy alcohol use in patients who may not be alcohol-dependent.
Dr. Katharine Bradley, MD, MPHAlcohol Use Disorders Identification Test (AUDIT)
A 10-item tool to screen for hazardous alcohol use, harmful use, and alcohol dependence.
World Health Organization Collaborative ProjectAmerican Shoulder and Elbow Surgeons (ASES) Shoulder Score
15-item assessment of shoulder pain and functional limitations in activities of daily living.
Dr. Robin R. Richards, MD, FRCSC, FAAOS, FAOABehavioral Activity Rating Scale (BARS)
A 1-item rating scale to quantify a patient's level of agitation in acute care or psychiatric settings.
Drug Abuse Screening Test (DAST-10)
A patient self-report questionnaire to screen for problematic drug use (excluding alcohol/tobacco).
Dr. Harvey A. Skinner, Ph.D.Foot and Ankle Ability Measure (FAAM)
Assesses functional limitations and disability related to foot and ankle conditions in daily activities and sports.
Dr. Jesse Van Swearingen, PhD, PT, FAPTAFoot and Ankle Disability Index (FADI)
Assess functional limitations of those with a variety of foot and ankle conditions
Dr. RobRoy Martin, PhD, PT, CSCSGeneral Anxiety Disorder (GAD-7)
Measure severity of anxiety
Dr. Robert L. Spitzer, MD